Alan Menter

Summary

Affiliation: Baylor University Medical Center
Country: USA

Publications

  1. ncbi The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis
    Alan Menter
    Baylor University Medical Center, Dallas, Texas, USA
    J Am Acad Dermatol 54:61-3. 2006
  2. ncbi The effect of psoriasis on patients' quality of life and improvements associated with alefacept therapy
    Alan Menter
    Baylor University Medical Center, Texas Dermatology Associates, 5310 Harvest Hill Road, Suite 260, Dallas, TX 75230, USA
    J Cutan Med Surg 8:20-5. 2004
  3. ncbi Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb study
    Alan Menter
    Baylor University Medical Center, Dallas, Texas, USA
    Int J Dermatol 46:637-48. 2007
  4. ncbi Update on botulinum toxin for facial aesthetics
    Jennifer Clay Cather
    Texas Dermatology Research Institute, Baylor Medical University, Dallas, TX, USA
    Dermatol Clin 20:749-61. 2002
  5. ncbi Long-term management of plaque psoriasis with continuous efalizumab therapy
    Alan Menter
    Baylor University Medical Center, Dallas, Texas, USA
    J Am Acad Dermatol 54:S182-8. 2006
  6. ncbi Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics
    Alan Menter
    Baylor University Medical Center, Dallas, Texas, USA
    J Am Acad Dermatol 58:826-50. 2008
  7. ncbi Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies
    Alan Menter
    Baylor University Medical Center, Dallas, Texas, USA
    J Am Acad Dermatol 60:643-59. 2009
  8. ncbi Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions
    Alan Menter
    Psoriasis Research Center, Baylor University Medical Center, Dallas, Texas, USA
    J Am Acad Dermatol 65:137-74. 2011
  9. ncbi Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents
    Alan Menter
    Baylor University Medical Center, Dallas, Texas, USA
    J Am Acad Dermatol 61:451-85. 2009
  10. ncbi Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy
    Alan Menter
    Psoriasis Research Center, Baylor University Medical Center, Dallas, Texas, USA
    J Am Acad Dermatol 62:114-35. 2010

Detail Information

Publications86

  1. ncbi The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis
    Alan Menter
    Baylor University Medical Center, Dallas, Texas, USA
    J Am Acad Dermatol 54:61-3. 2006
    ..30 [1.26-4.19]). Alefacept provided incremental efficacy over 5 successive 12-week treatment courses...
  2. ncbi The effect of psoriasis on patients' quality of life and improvements associated with alefacept therapy
    Alan Menter
    Baylor University Medical Center, Texas Dermatology Associates, 5310 Harvest Hill Road, Suite 260, Dallas, TX 75230, USA
    J Cutan Med Surg 8:20-5. 2004
    ..Alefacept helps fulfill the needs of psoriasis patients by providing efficacy, safety, off-treatment remissions, and improvement in QOL...
  3. ncbi Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb study
    Alan Menter
    Baylor University Medical Center, Dallas, Texas, USA
    Int J Dermatol 46:637-48. 2007
    ..To prevent rebound on discontinuation of efalizumab, this study evaluated the effectiveness of transitioning patients to an alternative psoriasis therapy...
  4. ncbi Update on botulinum toxin for facial aesthetics
    Jennifer Clay Cather
    Texas Dermatology Research Institute, Baylor Medical University, Dallas, TX, USA
    Dermatol Clin 20:749-61. 2002
    ..It is likely that the use of specific measuring devices, such as digital imaging, will further help define the use of botulinum toxin for different muscle groups and facial aesthetic indications...
  5. ncbi Long-term management of plaque psoriasis with continuous efalizumab therapy
    Alan Menter
    Baylor University Medical Center, Dallas, Texas, USA
    J Am Acad Dermatol 54:S182-8. 2006
  6. ncbi Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics
    Alan Menter
    Baylor University Medical Center, Dallas, Texas, USA
    J Am Acad Dermatol 58:826-50. 2008
    ..Finally, we will discuss the safety and efficacy of the biologic treatments used to treat patients with psoriasis...
  7. ncbi Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies
    Alan Menter
    Baylor University Medical Center, Dallas, Texas, USA
    J Am Acad Dermatol 60:643-59. 2009
    ....
  8. ncbi Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions
    Alan Menter
    Psoriasis Research Center, Baylor University Medical Center, Dallas, Texas, USA
    J Am Acad Dermatol 65:137-74. 2011
    ..In addition, we will update the prior 5 guidelines and address gaps in research and care that currently exist, while making suggestions for further studies that could be performed to help address these limitations in our knowledge base...
  9. ncbi Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents
    Alan Menter
    Baylor University Medical Center, Dallas, Texas, USA
    J Am Acad Dermatol 61:451-85. 2009
    ..We will also briefly discuss the available data for the use of azathioprine, fumaric acid esters, hydroxyurea, leflunomide, mycophenolate mofetil, sulfasalazine, tacrolimus, and 6-thioguanine in psoriasis...
  10. ncbi Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy
    Alan Menter
    Psoriasis Research Center, Baylor University Medical Center, Dallas, Texas, USA
    J Am Acad Dermatol 62:114-35. 2010
    ..Finally, where available, we will summarize the available data that compare the safety and efficacy of the different forms of UV light therapy...
  11. ncbi Comparing clobetasol propionate 0.05% spray to calcipotriene 0.005% betamethasone dipropionate 0.064% ointment for the treatment of moderate to severe plaque psoriasis
    Alan Menter
    Baylor Research Institute, Dallas, TX, USA
    J Drugs Dermatol 8:52-7. 2009
    ..003). Adverse events were reported by less than one-third of patients from each treatment group (31% for CP spray and 33% for C-BD ointment)...
  12. ncbi An open-label, multicenter study of the efficacy and safety of an AM/PM treatment regimen with clobetasol propionate spray 0.05% and calcitriol ointment 3 microg/g in the management of plaque psoriasis
    Alan Menter
    Baylor Research Institute, Dallas, Texas, USA
    Cutis 88:46-51. 2011
    ..05% treatment in the morning and calcitriol ointment 3 microg/g in the evening is efficacious and without unexpected safety issues for the management of moderate plaque psoriasis...
  13. ncbi Adverse drug events in infliximab-treated patients compared with the general and psoriasis populations
    Alan Menter
    Psoriasis Research Unit, Baylor Research Institute, Dallas, TX, USA
    J Drugs Dermatol 7:1137-46. 2008
    ..Infliximab is indicated for severe plaque psoriasis (PsO). The investigators compared safety event rates in infliximab PsO trials with those of the general United States and PsO populations...
  14. ncbi Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials
    Caitriona Ryan
    Department of Dermatology, Baylor Research Institute, 3900 Junius St, Ste 125, Dallas, TX 75246, USA
    JAMA 306:864-71. 2011
    ..Preliminary reports of major adverse cardiovascular events (MACEs) in psoriasis patients receiving anti-IL-12/23 agents have prompted concern...
  15. ncbi Psoriasis and its treatment with infliximab-mediated tumor necrosis factor alpha blockade
    Laura Winterfield
    Department of Dermatology, University of Texas Southwestern Medical School, Dallas, TX, USA
    Dermatol Clin 22:437-47, ix. 2004
    ..Comprehensive evaluation in controlled trials may allow infliximab to take its place among the expanding group of biologic drugs for the treatment of moderate to severe psoriasis...
  16. ncbi Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis
    Alan Menter
    Baylor Psoriasis Research Institute, Baylor University Medical Center, Dallas, TX 75246, USA
    J Am Acad Dermatol 63:448-56. 2010
    ....
  17. ncbi Atypical presentation of histoplasmosis in a patient with psoriasis and psoriatic arthritis on infliximab therapy
    Qurat Ul Ain Kamili
    Baylor Research Institute, Dallas, TX 75246, USA
    J Drugs Dermatol 9:57-60. 2010
    ..In addition, the authors emphasize the role of a multi-disciplinary approach and appropriate coordination among caregivers...
  18. ncbi Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis
    Alan Menter
    Baylor University Medical Center, Dallas, TX, USA
    Arch Dermatol 141:31-8. 2005
    ..Conclusion Extending efalizumab treatment from 12 to 24 weeks leads to improved efficacy and maintenance of quality of life with no evidence of cumulative toxic effects noted in patients with moderate to severe chronic plaque psoriasis...
  19. ncbi Combining traditional agents and biologics for the treatment of psoriasis
    Jennifer Clay Cather
    Baylor University Medical Center, Dallas, TX, USA
    Semin Cutan Med Surg 24:37-45. 2005
    ..A review of the literature, plus our personal experience in using combinations of traditional agents and biologics, is presented...
  20. ncbi The use of cyclosporine in dermatology: part II
    Caitriona Ryan
    Department of Dermatology at Baylor University Medical Center, Dallas, Texas 75246, USA
    J Am Acad Dermatol 63:949-72; quiz 973-4. 2010
    ....
  21. ncbi The status of biologic therapies in the treatment of moderate to severe psoriasis
    Alan Menter
    Psoriasis Research Unit, Baylor Research Institute, Dallas, Texas, USA
    Cutis 84:14-24. 2009
    ..Prospective trials of this sort are therefore needed to better understand the potential risks and benefits of such approaches...
  22. ncbi Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
    Alan Menter
    Division of Dermatology, Baylor Research Institute, University of Texas Southwestern Medical School, 3900 Junius St, 125, Dallas, TX 75246 1613, USA
    J Am Acad Dermatol 58:106-15. 2008
    ..Adalimumab is a fully human monoclonal antibody that binds tumor necrosis factor, a key proinflammatory cytokine involved in the pathogenesis of psoriasis...
  23. ncbi Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis
    Alan Menter
    Baylor Medical Center, Dallas, Texas, USA
    J Drugs Dermatol 3:27-38. 2004
    ....
  24. ncbi Current and future management of psoriasis
    Alan Menter
    Baylor Research Institute and Southwestern Medical School, Dallas, Texas 75246, USA
    Lancet 370:272-84. 2007
    ..Other innovative treatments are undergoing clinical studies, with the aim of maintaining safe, long-term control of the condition...
  25. ncbi Alefacept revisited: Our 3-year clinical experience in 200 patients with chronic plaque psoriasis
    Amy Perlmutter
    Baylor Research Institute, Dallas, Texas 75246, USA
    J Am Acad Dermatol 58:116-24. 2008
    ..A proportion of patients responding to therapy have been reported to experience remissions of approximately 7 to 8 months, characterized by disease-free and treatment-free intervals...
  26. ncbi A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis
    Alan Menter
    Division of Dermatology, Baylor University Medical Center, UT Southwestern Medical School, 5310 Harvest Hill Rd, Ste 260, Dallas, TX 75230, USA
    J Am Acad Dermatol 56:31.e1-15. 2007
    ..Previous studies of infliximab in psoriasis have demonstrated rapid improvement with induction therapy and sustained response with regularly administered maintenance therapy...
  27. ncbi Modulating T cell responses for the treatment of psoriasis: a focus on efalizumab
    Jennifer Clay Cather
    Department of Internal Medicine, Baylor University Medical Center, Dallas, Texas, USA
    Expert Opin Biol Ther 3:361-70. 2003
    ....
  28. ncbi Infliximab treatment for psoriasis in 120 patients on therapy for a minimum of one year: a review
    Qurat Ul Ain Kamili
    Department of Internal Medicine, Baylor College of Medicine, Houston, TX, USA
    J Drugs Dermatol 10:539-44. 2011
    ....
  29. ncbi Relapse, rebound, and psoriasis adverse events: an advisory group report
    Wayne Carey
    Royal Victoria Hospital, Montreal, Quebec, Canada
    J Am Acad Dermatol 54:S171-81. 2006
    ....
  30. ncbi Topical monotherapy with clobetasol propionate spray 0.05% in the COBRA trial
    Alan Menter
    Baylor Psoriasis Research Center, Baylor Research Institute, Dallas, Texas, USA
    Cutis 80:12-9. 2007
    ..Based on these data, clobetasol propionate spray 0.05% is an effective and convenient topical monotherapy for moderate to severe plaque psoriasis...
  31. ncbi The latest advances in pharmacogenetics and pharmacogenomics in the treatment of psoriasis
    Caitriona Ryan
    Department of Dermatology, Baylor Research Institute, Dallas, Texas, USA
    Mol Diagn Ther 14:81-93. 2010
    ....
  32. ncbi Efalizumab: continuous therapy for chronic psoriasis
    Jennifer Clay Cather
    Baylor University Medical Center, 5310 Harvest Hill Rd, Ste. 260, Dallas, TX75230, USA
    Expert Opin Biol Ther 5:393-403. 2005
    ..Efalizumab may thus potentially offer patients a safe option for long-term safe control in managing their disease...
  33. ncbi The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial
    Alan Menter
    Baylor Psoriasis Research Institute, Dallas, TX, USA
    J Am Acad Dermatol 62:812-8. 2010
    ..Psoriasis is associated with health-related quality-of-life impairment and depression...
  34. ncbi The use of cyclosporine in dermatology: part I
    Karrie T Amor
    Department of Dermatology at the University of Texas, Houston, Texas, USA
    J Am Acad Dermatol 63:925-46; quiz 947-8. 2010
    ....
  35. ncbi Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial
    Kim A Papp
    Probity Medical Research, Waterloo, Ontario, Canada
    Int J Dermatol 45:605-14. 2006
    ..To provide safety data for efalizumab, a recombinant humanized monoclonal IgG(1) antibody, in adults with chronic plaque psoriasis...
  36. ncbi Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial
    Kenneth B Gordon
    Loyola University Medical Center, Maywood, Ill 60153, USA
    JAMA 290:3073-80. 2003
    ..Because T-cell interactions are involved in the pathophysiology of psoriasis, therapy with a T-cell modulator may have beneficial effects on psoriasis severity and health-related quality of life (HRQL)...
  37. ncbi Clobetasol propionate spray 0.05% for the treatment of moderate to severe plaque psoriasis
    Alan Menter
    Baylor Psoriasis Research Center, Baylor Research Institute, Baylor University Medical Center, 3900 Junius St, Ste 145, Dallas, TX 75246, USA
    Cutis 89:89-94. 2012
    ..05%. Clobetasol propionate spray 0.05% is a topical product with a documented efficacy and safety profile with good acceptability in patients with moderate to severe plaque psoriasis...
  38. ncbi Practical considerations in future psoriasis therapies
    Christy Riddle
    Department of Internal Medicine, Baylor University Medical Center, 3500 Gaston Avenue, Dallas, TX 75246, USA
    Dermatol Clin 22:487-92, x. 2004
    ..Several tiers of psoriasis care are outlined to encourage individual physicians to choose the optimum level of service compatible with their individual practices...
  39. ncbi Topical treatment of psoriasis
    Qurat Ul Ain Kamili
    Psoriasis Research Unit, Baylor Research Institute, Dallas, Texas, USA
    Curr Probl Dermatol 38:37-58. 2009
    ..This will help alleviate the common problem of poor patient adherence, and inevitably result in more optimal clinical outcomes...
  40. ncbi Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial
    Alexa B Kimball
    Clinical Unit for Research Trials in Skin CURTIS, Massachusetts General and Brigham and Women s Hospitals, Harvard Medical School, 50 Staniford St, No 246, Boston, MA 02114, USA
    Arch Dermatol 144:200-7. 2008
    ..To investigate the efficacy and safety of ABT-874, an interleukin 12/23 monoclonal antibody, in psoriasis...
  41. ncbi Repeat courses of intravenous alefacept in patients with chronic plaque psoriasis provide consistent safety and efficacy
    Nick J Lowe
    Clinical Research Specialists, Santa Monica, California, USA
    Int J Dermatol 42:224-30. 2003
    ..This open-label study evaluated the safety and tolerability, efficacy, and pharmacodynamics of repeat courses of alefacept in men and women with chronic plaque psoriasis. This article reports the interim results of this ongoing study...
  42. ncbi Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis
    Dennis A Revicki
    Center for Health Outcomes Research, United BioSource Corporation, Bethesda, MD 20814, USA
    Dermatology 216:260-70. 2008
    ..However, the association between HRQOL outcomes and more substantial degrees of Psoriasis Area and Severity Index (PASI) response and physician and patient global ratings remains ill defined...
  43. ncbi Changing paradigms in dermatology: nuclear hormone receptors
    Laura Winterfield
    Department of Dermatology University of Texas Southwestern Medical School, Dallas, Texas 75390 7208, USA
    Clin Dermatol 21:447-54. 2003
    ..The current understanding of NHRs and future directions for NHR ligands in dermatology are discussed...
  44. ncbi Infliximab
    Laura S Winterfield
    Department of Dermatology, University of Texas Southwestern Medical School, Dallas, Texas, USA
    Dermatol Ther 17:409-26. 2004
    ..Practical issues such as patient selection, monitoring, cost, and potential combination therapies are also discussed...
  45. ncbi Rationale for the use of topical corticosteroids in melasma
    Alan Menter
    Division of Dermatology, Baylor University Medical Center, Dallas, Texas, USA
    J Drugs Dermatol 3:169-74. 2004
    ..01% suppresses biosynthetic and secretory functions of melanocytes, and thus melanin production, leading to early response in melasma, synergy among the three agents, and no significant side effects over an 8-week period...
  46. ncbi Case studies in severe psoriasis: A clinical strategy
    Mark Lebwohl
    Department of Dermatology, Mount Sinai School of Medicine, 1 Gustave Levy Place, Box 1047, New York, NY 10029-6574, USA
    J Dermatolog Treat 14:26-46. 2003
    ..The purpose of the algorithms is to make optimum use of phototherapy, traditional cytotoxic and immunosuppressive agents, retinoids, and newer biologic agents...
  47. ncbi Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial
    Craig L Leonardi
    Saint Louis University School of Medicine, St Louis, Missouri, USA
    J Am Acad Dermatol 52:425-33. 2005
    ..Efalizumab inhibits multiple T-cell-mediated processes...
  48. ncbi Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis
    Alice B Gottlieb
    Clinical Research Center, UMDNJ Robert Wood Johnson Medical School, New Brunswick, NJ 08901 0019, USA
    Clin Immunol 111:28-37. 2004
    ..Reduction in lesional, activated T cells induces improvement in psoriatic plaques. Galiximab (IDEC-114), an IgG(1) anti-CD80 antibody, binds to CD80, a costimulatory molecule involved in T-cell activation...
  49. ncbi Utilization of narrow-band ultraviolet light B therapy and etanercept for the treatment of psoriasis (UNITE): efficacy, safety, and patient-reported outcomes
    Leon Kircik
    Department of Dermatology, Indiana University School of Medicine, Indianapolis, IN, USA
    J Drugs Dermatol 7:245-53. 2008
    ..Etanercept and narrow-band ultraviolet light B (NB-UVB) are widely used to treat this disease...
  50. ncbi Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial
    Alice B Gottlieb
    University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USA
    J Am Acad Dermatol 51:534-42. 2004
    ..Tumor necrosis factor-alpha is a key mediator in the pathogenesis of psoriasis. Infliximab is a monoclonal antibody that specifically binds to tumor necrosis factor-alpha, blocking its biologic activity...
  51. ncbi Current investigational drugs in psoriasis
    Caitriona Ryan
    Department of Dermatology, Baylor University Medical Center, 3900 Junius Street, Suite 125, Dallas, TX 75204, USA
    Expert Opin Investig Drugs 21:473-87. 2012
    ..A concerted effort will need to be made among researchers, clinicians and patient advocacy groups to ensure new therapeutic agents are developed and gain proper exposure...
  52. ncbi One-week treatment with once-daily fluorouracil cream 0.5% in participants with actinic keratoses
    Alan Menter
    Baylor University Medical Center, Division of Dermatology, Dallas, TX 75246, USA
    Cutis 81:509-16. 2008
    ..Using this short treatment duration period in combination with cryosurgery may prove beneficial in clinical practice. Extending treatment for up to 4 weeks will further improve AK lesion clearance rates...
  53. ncbi Palmoplantar psoriasis: a phenotypical and clinical review with introduction of a new quality-of-life assessment tool
    Elizabeth Farley
    Baylor University Medical Center, Dallas, Texas, USA
    J Am Acad Dermatol 60:1024-31. 2009
    ..Palmoplantar psoriasis is associated with significant quality-of-life issues. Its epidemiology and phenotypical expression remain ill defined...
  54. ncbi PsEma--a hitherto unnamed dermatologic entity with clinical features of both psoriasis and eczema
    William Abramovits
    Department of Dermatology, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA
    Skinmed 4:275-81. 2005
    ..The authors have observed significant overlap between these two conditions such that a distinction between them may not always be made, even with histologic examination of skin biopsy specimens...
  55. ncbi Comorbidities in psoriasis patients
    Noori Kim
    University of Texas Southwestern, Dallas, TX
    Semin Cutan Med Surg 29:10-5. 2010
    ..Psoriasis, with its comorbidities, must be approached in a multidisciplinary manner to effectively and comprehensively understand, manage, and treat those with this complex disorder...
  56. ncbi A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasis
    Craig L Leonardi
    St Louis University School of Medicine, St Louis, MO 63117, USA
    Dermatology 213:204-14. 2006
    ..Efalizumab is a recombinant monoclonal immunoglobulin G1 (IgG1) antibody approved for use in psoriasis patients...
  57. ncbi Efficacy and safety of a new triple-combination agent for the treatment of facial melasma
    Susan C Taylor
    Dermatology Associates, St Luke s Roosevelt Hospital, New York, New York 10025, USA
    Cutis 72:67-72. 2003
    ..The most common adverse reactions seen with all treatment groups were erythema, skin peeling, burning, and/or stinging sensation. The majority of treatment-related adverse events were of mild severity...
  58. ncbi A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis
    Christopher S Carlin
    Department of Dermatology, University of Utah Health Sciences Center, Salt Lake City, Utah 84132, USA
    J Am Acad Dermatol 50:859-66. 2004
    ..We conclude that PASI 50 equates to a clinically meaningful improvement in psoriasis and represents a discerning primary endpoint...
  59. ncbi Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study
    Carin Gribetz
    Mt Sinai School of Medicine, Department of Dermatology, New York, New York, USA
    J Am Acad Dermatol 51:731-8. 2004
    ..0007). Adverse events were similar between groups. CONCLUSION: Pimecrolimus cream 1% is an effective treatment for inverse psoriasis with a rapid onset of action, and is safe and well-tolerated...
  60. ncbi Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics
    Alice Gottlieb
    Department of Dermatology, Tufts New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts, USA
    J Am Acad Dermatol 58:851-64. 2008
    ..We will discuss the use of disease-modifying antirheumatic drugs and the biologic therapies in the treatment of patients with moderate to severe psoriatic arthritis...
  61. ncbi Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis
    Dennis A Revicki
    Center for Health Outcomes Research, United BioSource Corporation, 7101 Wisconsin Avenue, Bethesda, MD 20814, USA
    J Dermatolog Treat 18:341-50. 2007
    ..The effect of adalimumab on patient-reported outcomes (PROs) was evaluated in patients with moderate to severe psoriasis during the initial 16-week, double-blind period of a 52-week, Phase III, multicenter trial...
  62. ncbi Calcitriol 3 microg/g ointment in the management of mild to moderate plaque type psoriasis: results from 2 placebo-controlled, multicenter, randomized double-blind, clinical studies
    Mark Lebwohl
    Department of Dermatology, Mount Sinai School of Medicine, New York, NY 10029 6574, USA
    J Drugs Dermatol 6:428-35. 2007
    ..Calcitriol 3 microg/g ointment has demonstrated good clinical efficacy as well as topical and systemic safety when used to treat psoriasis...
  63. ncbi Intestinal transport of aminopterin enantiomers in dogs and humans with psoriasis is stereoselective: evidence for a mechanism involving the proton-coupled folate transporter
    Alan Menter
    Baylor Research Institute, Dallas, Texas, USA
    J Pharmacol Exp Ther 342:696-708. 2012
    ..Collectively, our results demonstrate a strong in vitro-in vivo correlation implicating stereoselective transport by PCFT as the mechanism underlying stereoselective absorption observed in vivo...
  64. ncbi Novel therapies for psoriasis
    Jennifer Cather
    Baylor University Medical Center, Dallas, Texas, USA
    Am J Clin Dermatol 3:159-73. 2002
    ..For the 2 to 3% of the worldwide population of patients with psoriasis the future has never looked brighter...
  65. ncbi The use of ustekinumab in autoimmune disease
    Caitriona Ryan
    Baylor Research Institute, Department of Dermatology, 3900 Junius Street, Suite 1125, Dallas, Texas 75204, USA
    Expert Opin Biol Ther 10:587-604. 2010
    ..Ustekinumab is an antibody to the common p40 subunit of IL-12 and IL-23, which has been studied in the treatment of psoriasis, psoriatic arthritis, Crohn's disease and multiple sclerosis...
  66. ncbi The ethics of consulting with pharmaceutical companies
    Andrew Miner
    The University of Texas Southwestern, Dallas, TX, USA
    Clin Dermatol 27:339-45. 2009
    ..These include publication and prescribing bias. These also lead to the real or apparent conflict of interest when the consultant receives unearned, unjustified, or excessive compensation and gifts...
  67. ncbi Cardiocutaneous syndromes and associations
    Nagla F Abdelmalek
    Division of Dermatology and Cardiology, Department of Internal Medicine, Baylor University Medical Center, Dallas, TX, USA
    J Am Acad Dermatol 46:161-83; quiz 183-6. 2002
    ....
  68. ncbi Changing paradigms in dermatology: tumor necrosis factor alpha (TNF-alpha) blockade in psoriasis and psoriatic arthritis
    Frank C Victor
    Clinical Research Center, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, New Brunswick, New Jersey 08903, USA
    Clin Dermatol 21:392-7. 2003
    ..The role of TNF-alpha in the pathogenesis of psoriasis is reviewed, along with clinical trials demonstrating the efficacy of new anti-TNF-alpha immunobiologics in the treatment of psoriasis and psoriatic arthritis...
  69. ncbi Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell counts
    Kenneth B Gordon
    Department of Medicine, Division of Dermatology, Loyola University Medical Center, Maywood, IL 60153, USA
    Arch Dermatol 139:1563-70. 2003
    ..To examine the relationship between the pharmacodynamic and antipsoriatic effects of alefacept, a biologic agent that targets CD4+ and CD8+ memory T cells...
  70. ncbi A putative RUNX1 binding site variant between SLC9A3R1 and NAT9 is associated with susceptibility to psoriasis
    Cynthia Helms
    Department of Genetics, Washington University School of Medicine, St Louis, Missouri 63110, USA
    Nat Genet 35:349-56. 2003
    ..This is the second example of loss of a RUNX1 binding site associated with susceptibility to an autoimmune disease. It also suggests defective regulation of SLC9A3R1 or NAT9 by RUNX1 as a susceptibility factor for psoriasis...
  71. ncbi Ciclopirox gel in the treatment of patients with interdigital tinea pedis
    Raza Aly
    Department of Dermatology, University of California San Francisco, USA
    Int J Dermatol 42:29-35. 2003
    ..77% applied twice daily for 4 weeks is an effective treatment of moderate interdigital tinea pedis due to T. rubrum, T. mentagrophytes and E. floccosum and is associated with a low incidence of minor adverse effects...
  72. ncbi Tazarotene versus tazarotene plus hydroquinone in the treatment of photodamaged facial skin: a multicenter, double-blind, randomized study
    Nicholas Lowe
    UCLA School of Medicine, Santa Monica, CA, USA
    J Cosmet Laser Ther 8:121-7. 2006
    ..To compare the efficacy and tolerability of tazarotene plus hydroquinone versus tazarotene alone in the treatment of facial photodamage...
  73. ncbi Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array
    Xianghong Zhou
    Department of Biostatistics, Harvard University, Boston 02115, USA
    Physiol Genomics 13:69-78. 2003
    ....
  74. ncbi A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis
    Mark Lebwohl
    Departments of Dermatology, Mount Sinai Medical Center, New York, NY 10029 6574, USA
    Int J Dermatol 41:269-74. 2002
    ..A clobetasol propionate foam product is as effective as clobetasol propionate solution in the treatment of scalp psoriasis...
  75. ncbi Rethinking eligibility creep
    Maryanne Kazanis
    J Am Acad Dermatol 59:165-7; author reply 167. 2008
  76. ncbi Decision points for the initiation of systemic treatment for psoriasis
    Steven R Feldman
    Department of Dermatology, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157 1071, USA
    J Am Acad Dermatol 53:101-7. 2005
    ....
  77. ncbi Combination therapy to treat moderate to severe psoriasis
    Mark Lebwohl
    Department of Dermatology, Mount Sinai School of Medicine, Mt Sinai Medical Center, 5 E 98th Street, 12th Floor, New York, NY 10029 6574, USA
    J Am Acad Dermatol 50:416-30. 2004
    ....
  78. ncbi Effect of a single course of isotretinoin therapy on bone mineral density in adolescent patients with severe, recalcitrant, nodular acne
    John J DiGiovanna
    Division of Dermatopharmacology, Department of Dermatology, Brown Medical School Rhode Island Hospital, Providence, RI 02903, USA
    J Am Acad Dermatol 51:709-17. 2004
    ..The effect of short-term (4-5 months) therapy at the lower dose recommended for acne on bone development in younger, growing adolescent (12-17 years) patients has not been well studied...
  79. ncbi Clinical safety and efficacy studies of a novel formulation combining 1.2% clindamycin phosphate and 0.025% tretinoin for the treatment of acne vulgaris
    Joel Schlessinger
    Advanced Skin Research Center, Omaha, NE, USA
    J Drugs Dermatol 6:607-15. 2007
    ..Individual ingredients and the combination were well-tolerated. Among those treated with the combination formulation, discontinuation rates due to adverse events were 1% or less...
  80. ncbi A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci
    Ying Liu
    Division of Human Genetics, Department of Genetics, Washington University School of Medicine, St Louis, Missouri, United States of America
    PLoS Genet 4:e1000041. 2008
    ..This region harbors the interleukin 2 (IL2) and interleukin 21 (IL21) genes and was recently shown to be associated with four autoimmune diseases (Celiac disease, Type 1 diabetes, Grave's disease and Rheumatoid Arthritis)...
  81. ncbi Ciclopirox gel for seborrheic dermatitis of the scalp
    Raza Aly
    Department of Dermatology, University of California San Francisco, San Francisco, CA, USA
    Int J Dermatol 42:19-22. 2003
    ..CONCLUSION: Ciclopirox gel is effective and safe in the treatment of seborrheic dermatitis of the scalp...
  82. ncbi AAD consensus statement on psoriasis therapies
    Jeffrey P Callen
    J Am Acad Dermatol 49:897-9. 2003
  83. ncbi Localization of PSORS1 to a haplotype block harboring HLA-C and distinct from corneodesmosin and HCR
    Cynthia Helms
    Department of Genetics, Washington University School of Medicine, Box 8232, 4566 Scott Avenue, St Louis, Missouri, 63110, USA
    Hum Genet 118:466-76. 2005
    ..The introduction of a potential binding site for the RUNX/AML family of transcription factors in intron 7, is also specific to these HLA-C alleles. These variants need to be investigated further for their role as PSORS1...
  84. ncbi Definitions of measures of effect duration for psoriasis treatments
    Kenneth B Gordon
    Arch Dermatol 141:82-4. 2005
  85. ncbi A large 12-month extension study of an 8-week trial to evaluate the safety and efficacy of triple combination (TC) cream in melasma patients previously treated with TC cream or one of its dyads
    Helen Torok
    Trillium Creek Dermatology, Inc, Medina, OH 44526, USA
    J Drugs Dermatol 4:592-7. 2005
    ..Once daily application of TC cream applied intermittently over a long period is a safe, tolerable, and effective treatment for moderate to severe melasma of the face...
  86. ncbi Psoriasis and the metabolic syndrome
    Alice B Gottlieb
    Tufts Medical Center, Boston, MA 02111 1533, USA
    J Drugs Dermatol 7:563-72. 2008
    ..This article reviews the association of psoriasis with metabolic syndrome, as well as the impact of biologic agents that are currently used to treat psoriasis (ie, TNF antagonists) on risk factors for metabolic syndrome...